Everolimus fails to extend life in advanced liver cancer

hepatocellular carcinoma dreamstime

Survival rates in patients with advanced liver cancer are not improved by the mTOR inhibitor everolimus, the EVOLVE-1 clinical trial suggests[1]

The study followed 546 adults with advanced hepatocellular carcinoma (HCC) who were intolerant to or had experienced disease progression with sorafenib. They were randomly assigned to everolimus 7.5mg/day or placebo, with best supportive care.

Median overall survival rates did not differ between everolimus and placebo, at 7.6 versus 7.3 months. The results “extend the list of failed phase III studies in advanced HCC, highlighting the challenge of developing effective therapies for this cancer”, the investigators remark in



[1]  Zhu AX et al. JAMA 2014;312(1):57-67.

Last updated
The Pharmaceutical Journal, PJ, 12 July 2014, Vol 293, No 7818;293(7818):DOI:10.1211/PJ.2014.20065674

You may also be interested in